Dyslipidaemia is the major risk factor for cardiovascular disease (CVD) which is the leading cause of death in the world. Even though several lipid parameters are used, currently apolipoprotein B (apoB) is considered as the best predictor of CVD. Thus this study was carried out to find out the association between conventional lipid parameters and apoB in apparently healthy subjects. A descriptive cross-sectional study was carried out in 170 apparently healthy volunteers who were not diagnosed with dyslipidaemia. After 12 hours overnight fast venous blood was obtained and Total cholesterol (TC), Triglyceride (TG), High density lipoprotein cholesterol (HDL-C) were measured by enzymatic kit method. Low density lipoprotein cholesterol (LDL-C) was calculated by Friedewald formula and apoB was analyzed by immune turbid metry using a Konelab® auto analyzer. Among the participants, majority (63.5%) were females. The mean value of apoB concentration of the population was 103 ± 42 mg/dL which was similar and not significantly different between the genders (Males, 102 ± 37 mg/dL and Females, 104 ± 45 mg/dL). All lipid parameters showed a positive correlation with apoB concentration whereas HDL-C had a negative correlation (r = -0.165). HDL-C significantly (p < 0.05) decreased with increase in apoB concentration while LDL-C, TC/HDL-C and non-HDL-C significantly (p < 0.05) increased with an increase in apoB concentration. Present study suggests that serum apoB has better correlations and associations with the parameters that are used in conventional lipid profile and with markers recommended for diagnosing dyslipidaemia. Hence apoB could be used as a single marker for screening dyslipidaemia in apparently healthy people.
References
[1]
World Health Organization (2013) Cardiovascular Diseases Fact Sheet N°317. http://www.who.int/mediacentre/factsheets/fs317/en/
[2]
Ministry of Healthcare and Nutrition (2009) The National Policy for Prevention and Control of Chronic Non Communicable Diseases. Ministry of Healthcare and Nutrition, Colombo, Sri Lanka.
[3]
Katulanda, P., Ranasinghe, P., Jayawardana, R., Sheriff, R. and Mathews, D.R. (2012) Metabolic Syndrome among Sri Lankan Adults: Prevalence, Patterns and Correlates. Diabetology & Metabolic Syndrome, 4, 1-10. http://dx.doi.org/10.1186/1758-5996-4-24
[4]
Misra, A., Luthra, K. and Vikram, N.K. (2004) Dyslipidemia in Asian Indians: Determinants and Significance. Journal of the Association of Physicians India, 52, 137-143.
[5]
Enas, E.A., Chacko, V., Pazhoor, S.G., Chennikkara, H. and Devarapalli, H.P. (2007) Dyslipidemia in South Asians Patients. Current Atherosclerosis Report, 9, 367-374. http://dx.doi.org/10.1007/s11883-007-0047-y
[6]
Herath, H.R.I.S., Katulanda, P., Mathews, D.R., Sheriff, M.H.R., Constantine, G.R. and De Vas Gunawardena, A.N.P., et al. (2010) Prevalence and Patterns of Dyslipidaemia among Adult Sri Lankan. 123rd Annual Academic Session, Sri Lanka Medical Association, Colombo, 15 June 2010.
[7]
Adult Treatment Panel III (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation, 106, 3143-3421.
[8]
Durrington, P.N. (2002) Can Measurement of Apolipoprotein B Replace the Lipid Profile in the Follow-Up of Patients with Lipoprotein Disorders? Clinical Chemistry, 48, 401-402.
[9]
Levinson, S.S. (2007) Comparison of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol for Identifying Coronary Artery Disease Risk Based on Receiver Operating Curve Analysis. American Journal of Clinical Pathology, 127, 449-455. http://dx.doi.org/10.1007/s11883-007-0047-y
[10]
Poonguzhali, D.V., Vinodhini, V.M., William, W. and Kumar, J.S. (2013) Evaluation of Apolipoprotein-B Levels in Dysglycemia. Asian Journal of Pharmaceuticals and Clinical Research, 6, 112-114.
[11]
Harpers, C.R. and Jacobson, T.A. (2010) Using Apolipoprotein B to Manage Dyslipidemic Patients: Time for a Change? Mayo Clinic Proceedings, 85, 440-445. http://dx.doi.org/10.4065/mcp.2009.0517
[12]
Nair, N. (2015) Should We Measure Apolipoproteins to Evaluate Coronary Heart Disease Risk? The NYU Langone Online Journal of Medicine. http://www.clinicalcorrelations.org/?p=5748
[13]
Zhang, L., Qiao, Q. and Dong, Y.H. (2012) Ethnic Difference in Lipid Profiles. In: Kelishadi, R., Ed., Dyslipidemia— From Prevention to Treatment, InTech. http://www.intechopen.com/books/dyslipidemia-from-prevention-to-treatment/ethnic-differences-in-lipid-profiles
[14]
Mukherjee, M., Srivastava, A., Kesari, A. and Mital, B. (2005) Analysis of VNTR Loci, ApoB 3’HVR and DIS80 in North Indians. Indian Journal of Biotechnology, 4, 358-362.
[15]
Tennakoon, S.U.B., Kumar, B.N., Nugegoda, D.B. and Meyer, H.E. (2010) Comparison of Cardiovascular Risk Factors between Sri Lankans Living in Kandy and Oslo. BMC Public Health, 10, 1-8. http://dx.doi.org/10.1186/1471-2458-10-654
[16]
Miremadi, S., Sniderman, A. and Frohlich, J. (2010) Can Measurement of Serum Apolipoprotein B Replace the Lipid Profile Monitoring Patients with Lipoprotein Disorders? Clinical Chemistry, 48, 484-488.
[17]
Vishwanath, P., Prashant, A., Acharya, A., Suma, M.N., Kiran, H.S. and Karthik, G. (2012) Use of Anthropometric Indices as Simple Predictors of Deranged Lipid Profile and at Risk Population for Future Cardiovascular Events. International Journal of Health& Allied Science, 1, 8-12. http://dx.doi.org/10.4103/2278-344X.96411
[18]
Wallidus, G. and Jungner, I. (2005) Rationale for Using Apolipoprotein B and Apolipoprotein A-I as Indicators of Cardiac Risk and as Targets for Lipid-Lowering Therapy. European Heart Journal, 26, 210-212. http://dx.doi.org/10.1093/eurheartj/ehi077
[19]
Siniawski, D.A., Masson, W., Sorroche, P., Casanas, L., Krauss, J. and Cagide, A. (2010) Correlation between Apolipoprotein B to Apolipoprotein A1 Ratio and Total to HDL Cholesterol Ratio in a Healthy Population. Should Castelli Index Be Updated? Revista Argeninat de Cardioogia, 79, 33-38.
[20]
Katulanda, G.W., Katulanda, P., Sheriff, M.H.R., Matthews, D.R. and Brian, S. (2009) Comparison of Apolipoproteins B and A1 in People with versus without Metabolic Syndrome. 122nd Anniversary Academic Session, Sri Lanka Medical Association, Colombo, 32 March 2009.
